The Centers for Disease Control and Prevention on Wednesday released guidance advising practitioners to offer an HIV prevention pill to healthy individuals who are at high risk for an HIV infection, according to published reports.
Antiretroviral drugs have allowed people with HIV to live normal life spans, but because of this, they also are susceptible to many new health complications, according to care guidelines released Thursday by the Infectious Diseases Society of America.
Walgreens recently presented research from two retrospective cohort studies exploring HIV and comorbid medication adherence at HIV-specialized pharmacies and the implications for HIV patients with serious mental illness.
The U.S. Food and Drug Administration on Monday approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy, a combination of medicines used to treat HIV infection.
The Food and Drug Administration will not decide whether to approve a drug for diarrhea in HIV patients as it continues to review the regulatory approval application for it, the drug's manufacturer said.
After it was first identified as the cause of AIDS in 1983, being diagnosed with an HIV infection was a literal death sentence, and it remains that way for many people in poor countries who lack access to the life-saving medications that have transformed HIV from a sure ticket to death into a chronic illness.
Patients with HIV who immediately started antiretroviral therapy significantly reduced the risk of spreading the virus to an uninfected partner, compared with those who delayed therapy, according to results of a multinational study. The study also found that antiretroviral therapy reduced the risk of transmission by 96%.